Intellipharmaceutics International (IPCIF) Stock Price, News & Analysis

Company Overview

Intellipharmaceutics International Inc. is a Canada-based specialty pharmaceutical company focused on the development, licensing and commercialization of innovative drug delivery technologies. Established in the late 1990s and headquartered in Toronto, the company’s core expertise lies in creating controlled­-release oral formulations, inhalation and pulmonary delivery systems, as well as buccal and transdermal therapies. Through its proprietary IntelliDose® and IntelliCap® platforms, Intellipharmaceutics aims to improve drug bioavailability, patient compliance and therapeutic outcomes for a variety of active pharmaceutical ingredients.

The company’s product pipeline addresses multiple therapeutic areas, including diabetes management, pain relief, cardiovascular disorders and hormone replacement. Intellipharmaceutics works closely with global pharmaceutical partners to conduct preclinical research, clinical trials and regulatory submissions. Its modular development approach allows for rapid scale-up and technology transfer, enabling partners to bring improved formulations to market with reduced time and cost.

While based in Canada, Intellipharmaceutics serves markets in North America, Europe and Asia through strategic alliances and licensing arrangements. The company operates specialized laboratories for formulation design and analytical testing, and maintains collaborative networks with contract research organizations and academic institutions. This global footprint supports multi­center clinical programs and facilitates access to diverse patient populations.

Intellipharmaceutics is led by a management team with extensive experience in pharmaceutical development and commercialization. Supported by a board of directors with backgrounds in biotechnology, intellectual property and regulatory affairs, the company continues to advance its next­ generation delivery platforms. With a focus on innovation and partnership, Intellipharmaceutics is positioned to address unmet medical needs and drive value for stakeholders in the specialty pharma sector.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 12,042 shs
• Market Capitalization: $4.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IPCIF Stock Analysis - Frequently Asked Questions

How were Intellipharmaceutics International's earnings last quarter?

Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) posted its quarterly earnings data on Monday, July, 16th. The company reported ($0.70) EPS for the quarter, meeting analysts' consensus estimates of ($0.70). The company had revenue of $0.58 million for the quarter, compared to analyst estimates of $0.90 million.

When did Intellipharmaceutics International's stock split?

Intellipharmaceutics International's stock reverse split on the morning of Friday, September 14th 2018.The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Intellipharmaceutics International?

Shares of IPCIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 7/16/2018
• Today: 7/12/2025
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IPCIF
• CIK: 1474835
• Web: www.intellipharmaceutics.com
• Phone: 416-798-3001
• Fax: 416-798-3007
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $660 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.32) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,093,000
• Free Float: 32,511,000
• Market Cap: $4.96 million
• Optionable: Not Optionable
• Beta: 1.53